By Manuela Bianco Suarez University of Kentucky Healthcare This winter, low temperatures have impacted the state of Kentucky. One of the biggest concerns statewide is the rise in the number of ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Marc Watkins, M.D., chief medical officer at Kroger Health, discusses RSV and how people can protect themselves and their ...

As Robert F. Kennedy Jr.’s hearing to head the Department of Health and Human Services is scheduled to begin Wednesday, health care officials have been prepared to educate the public on vaccines and ...

The Centers for Disease Control and Prevention recently issued a warning about the rise in respiratory illnesses like the flu, COVID, and RSV. The CDC also ranked our State as "very high risk." ...

Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the ...

A Prince George doctor and parent of a prematurely born child is calling for a new life-saving vaccine to be made available ...

RSV is a contagious virus causing severe respiratory infections in infants. Vaccination during pregnancy, provides newborns ...

Toronto Public Health recorded over 570 cases of influenza and a nearly 11 per cent COVID-19 positivity rate in the second week of January.

When given to expectant mothers, the vaccine is expected to also protect their babies until they are six months old. Respiratory syncytial virus causes cold-like symptoms for many people but ...

Despite more than 50 years of research, there are no RSV vaccines approved or in Phase III clinical trials. Key challenges include peak disease in infants less than 3 months of age and ...